{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:50:38Z","timestamp":1782924638795,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>This case report describes a 30-year old male diagnosed with schizophrenia at the age of 23, and with a long history of drug abuse. He had previously received a wide range of antipsychotic drug treatment regimens, all with some degree of effect, but never with complete symptom relief. He was also suffering from persistent cognitive and negative symptoms. At the time of admission in our clinic, he was on Quetiapine (QUE) and Haloperidol (HAL). It was therefore decided to substitute HAL for Cariprazine (CAR)\u2014an agent with a novel pharmacological and clinical profile\u2014in the hope of gaining increased efficacy, particularly in the cognitive and negative symptom domains. Within 3 weeks of the switch from HAL to CAR the patient clearly improved, and notably so in the aforementioned symptom areas. A number of subsequent adjustments of antipsychotic dosages and adjunct medications during the ensuing months resulted in an apparently more stable alleviation of positive as well as negative and cognitive symptoms, including markedly improved personal and social capabilities. Interestingly, some time after initiating CAR treatment the patient also reported that from being a heavy smoker (60 cig\/d) he had cut down and eventually ceased smoking entirely; furthermore, he has remained clean of other substance abuse since his first admission in 2020. The joint treatment with CAR in combination with QUE thus seems to have improved the patient's cognitive functioning as well as possibly his susceptibility to substance abuse.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.727666","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:22:01Z","timestamp":1629264121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction"],"prefix":"10.3389","volume":"12","author":[{"given":"Jose","family":"Rodriguez Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sahlsten Sch\u00f6lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/14737167.2014.894463","article-title":"Burden of schizophrenia on selected comorbidity costs","volume":"14","author":"Lafeuille","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31887\/DCNS.2006.8.1\/bwinklbaur","article-title":"Substance abuse in patients with schizophrenia","volume":"8","author":"Winklbaur","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/0004867414561526","article-title":"Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation","volume":"49","author":"Sara","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"key":"B5","volume-title":"Kaplan and Sadock's Synopsis of Psychiatry","author":"Sadock","year":"2015"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post-hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"Nemeth","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/NDT.S298005","article-title":"Cariprazine in three acute patients with schizophrenia: a real-world experience","volume":"17","author":"Montes","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B10","first-page":"36","article-title":"Cariprazine may decrease substance abuse in patients with bipolar I disorder","author":"Sanders","year":"2019","journal-title":"Psychiatric Times"},{"key":"B11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1017\/9781107607330","volume-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2016"},{"key":"B13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/00005053-199004000-00009","article-title":"Persistent auditory hallucinations and their relationship to delusions and mood","volume":"178","author":"Hustig","year":"1990","journal-title":"J Nerv Ment Dis"},{"key":"B14","article-title":"Cognitive improving properties of cariprazine, a dopamine D3 receptor preferring partial agonist: overview of non-clinical and clinical data","author":"Laszlovszky","year":"2019","journal-title":"27th European Congress of Psychiatry"},{"key":"B15","article-title":"Cognitive-improving properties of cariprazine, a dopamine D3 receptor-preferring partial agonist: overview of non-clinical and clinical data","author":"McIntyre","year":"2019","journal-title":"American Psychiatry Association (APA), Annual Meeting"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","article-title":"The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence","volume":"49","author":"Heidbreder","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","article-title":"The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders","volume":"5","author":"Sokoloff","year":"2006","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur J Neurosci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report","volume":"39","author":"Ricci","year":"2021","journal-title":"J Addict Dis"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.727666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T14:53:46Z","timestamp":1673103226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.727666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":19,"alternative-id":["10.3389\/fpsyt.2021.727666"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.727666","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"article-number":"727666"}}